Next Article in Journal
Role of CD38 in Adipose Tissue: Tuning Coenzyme Availability?
Previous Article in Journal
Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis—Mechanistic Insights into Anemia of Inflammation and Its Treatment
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 13
Issue 11
10.3390/nu13113733
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Narrative Review of Human Clinical Trials on the Impact of Phenolic-Rich Plant Extracts on Prediabetes and Its Subgroups

by
Wen Xin Janice Lim
1,2,
Cheryl S. Gammon
1,
Pamela von Hurst
3,
Lynne Chepulis
4 and
Rachel A. Page
5,6,*
1
School of Health Sciences, Massey University, Auckland 0632, New Zealand
2
Riddet Institute, Massey University, Palmerston North 4442, New Zealand
3
School of Sport, Exercise and Nutrition, Massey University, Auckland 0632, New Zealand
4
Waikato Medical Research Centre, Te Huataki Waiora School of Health, University of Waikato, Hamilton 3216, New Zealand
5
School of Health Sciences, Massey University, Wellington 6021, New Zealand
6
Centre for Metabolic Health Research, Massey University, Auckland 0632, New Zealand
*
Author to whom correspondence should be addressed.
Nutrients 2021, 13(11), 3733; https://doi.org/10.3390/nu13113733
Submission received: 15 September 2021 / Revised: 17 October 2021 / Accepted: 21 October 2021 / Published: 22 October 2021
(This article belongs to the Section Phytochemicals and Human Health)
Versions Notes

Abstract

:
Phenolic-rich plant extracts have been demonstrated to improve glycemic control in individuals with prediabetes. However, there is increasing evidence that people with prediabetes are not a homogeneous group but exhibit different glycemic profiles leading to the existence of prediabetes subgroups. Prediabetes subgroups have been identified as: isolated impaired fasting glucose (IFG), isolated impaired glucose tolerance (IGT), and combined impaired fasting glucose and glucose intolerance (IFG/IGT). The present review investigates human clinical trials examining the hypoglycemic potential of phenolic-rich plant extracts in prediabetes and prediabetes subgroups. Artemisia princeps Pampanini, soy (Glycine max (L.) Merrill) leaf and Citrus junos Tanaka peel have been demonstrated to improve fasting glycemia and thus may be more useful for individuals with IFG with increasing hepatic insulin resistance. In contrast, white mulberry (Morus alba Linn.) leaf, persimmon (Diospyros kaki) leaf and Acacia. Mearnsii bark were shown to improve postprandial glycemia and hence may be preferably beneficial for individuals with IGT with increasing muscle insulin resistance. Elaeis guineensis leaf was observed to improve both fasting and postprandial glycemic measures depending on the dose. Current evidence remains scarce regarding the impact of the plant extracts on glycemic control in prediabetes subgroups and therefore warrants further study.

1. Introduction

Globally, diabetes rates have been increasing at an alarming rate. In 2019, it was estimated that 463 million (ages 20–79 years) (9.3%) people were living with diabetes worldwide, an increase of 62% from 2009 with the number expected to increase to 700 million (10.9%) by 2045 [1]. According to the International Diabetes Federation (IDF), the current annual global health expenditure on diabetes is estimated to be USD 760 billion and is projected to reach USD 845 billion by 2045 [1]. Much of the health costs come from the complications that are associated with diabetes, which can affect the eyes, kidneys and nervous system [2,3], and heighten the risk of cardiovascular morbidity and mortality [4].
Although the rates of Type 1 diabetes mellitus have also been the main driver of the increased rates of diabetes, it is Type 2 diabetes mellitus (T2DM) that constitutes approximately 90% of diabetes worldwide [1]. This has largely occurred in parallel with the obesity epidemic. Given the burden this is putting and will put on health systems, it is therefore crucial to identify strategies that would prevent or slow the development of T2DM.

1.1. Prediabetes and Its Subgroups

Prediabetes is an intermediate state of hyperglycemia with blood glucose levels above normal but not high enough to be classified as T2DM [5]. Prediabetes is a high-risk state for developing T2DM [6] and has an annual conversion rate of 5–10% [5,7]. Therefore, early detection of prediabetes in conjunction with effective interventions may reduce the risk of developing future T2DM [8,9].
There is increasing awareness that individuals with prediabetes are not a homogeneous group [10,11] and different metabolic profiles exist reflecting varying degrees of insulin resistance and β-cell dysfunction [10]. Three subgroups of glucose intolerance have been identified, which are impaired fasting glucose (IFG), isolated impaired glucose tolerance (IGT), and combined impaired fasting glucose and impaired glucose tolerance (IFG/IGT) [10,12]. These subgroups have distinctly different glycemic metabolic profiles [7,13,14,15,16,17,18,19,20,21], and exhibit different postprandial glucose (PG) and postprandial insulin (PI) shapes after a carbohydrate load [17,20,21,22,23].
According to the American Diabetes Association (ADA) guidelines, individuals with isolated IFG have elevated fasting blood glucose (FBG) of 100–125 mg/dL (5.6–6.9 mmol/L) while having a normal 2 h postprandial glucose (2hPG) of <140 mg/dL (<7.8 mmol/L) [24]. Individuals with IFG tend to exhibit increased endogenous glucose production (EGP), reduced hepatic insulin sensitivity, stationary β-cell dysfunction and/or chronic low β-cell mass, defective early phase insulin secretion while maintaining normal second phase insulin secretion with PG returning to normal after 2 h, altered glucagon-like peptide-1 (GLP-1) secretion and inappropriately elevated glucagon secretion [12,13,20,21,22,23,25,26,27,28,29,30,31,32,33]. They tend to also possess healthy or near healthy peripheral insulin sensitivity [20,25,27,29].
Individuals with isolated IGT typically have normal FBG of <100 mg/dL (<5.6 mmol/L), but an abnormally elevated 2hPG of 140–199 mg/dL (7.8–11.0 mmol/L) [24]. Characteristics specific to IGT may include increased or normal EGP, reduced peripheral insulin sensitivity, near-normal hepatic insulin sensitivity, impaired early and late phase insulin secretion with a subsequent rise in PG that is unable to return to normal baseline after 2 h, persistent and progressive loss of β-cell function, reduced secretion of gastric inhibitory polypeptide (GIP) and inappropriately elevated glucagon secretion [12,13,20,21,22,23,25,26,27,28,29,30,33,34,35].
Individuals with combined IFG/IGT fulfill both criteria of having elevated FBG of 100–125 mg/dL (5.6–6.9 mmol/L) and elevated 2hPG of 140–199 mg/dL (7.8–11.0 mmol/L) [24]. IFG/IGT takes the worse form of impaired glucose control with a reduced glucagon suppression, impaired hepatic and peripheral insulin sensitivity and progressive loss of β-cell function, with a sustained rise in PG that does not return to normal baseline after 2 h [20,21,29,36,37].

1.2. Proposed Mechanisms of Action of Plant Extracts on Prediabetes Subgroups

Phenolic-rich plant extracts are increasingly being recognized for their hypoglycemic effects and potential to help regulate glucose metabolism in the human body [38,39,40,41,42,43,44,45,46,47,48,49]. The complex and unique phenolic structures of the plant extracts such as the number and position of hydrogen moieties (e.g., OH) and double bonds determine their bioavailability and subsequent interaction with membrane-bound brush border enzymes, apically located transporters and receptors involved in glucose metabolic pathways [50,51,52]. The hypoglycemic properties of plant extracts provide the opportunity for their use as an alternative or to complement anti-diabetic medications with few to no adverse effects [53,54].
Anti-diabetic pharmacological drugs have targeted various organs, such as muscle, pancreas, liver and gut, responsible for glucose metabolism with specific mechanisms of action to improve glycemic control [54]. Drugs such as metformin belonging to the class of biguanide inhibit liver glucose production, whilst sulfonylureas and meglitinides that are insulin secretagogues target liver insulin resistance and therefore are utilized to treat IFG or IFG/IGT to improve fasting glycemic responses [20,55,56]. In contrast, drugs targeting peripheral or muscle insulin resistance to improve skeletal muscle insulin sensitivity such as peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists, as well as α-glucosidase inhibitors, GLP-1 agonists, dipeptidyl peptidase-4 (DPP4) inhibitors and thiazolidinediones, are most efficacious when taken together with a meal to improve postprandial glycemic responses and hence, may be better utilized by those with IGT or IFG/IGT [20].
Similarly, plant extracts have been demonstrated to modulate specific glycemic pathways in carbohydrate metabolism. Plant extracts that may protect β-cell function against glucotoxicity via activating 5′AMP-activated protein kinase (AMPK), suppress hepatic gluconeogenesis, stimulate insulin secretion and reduce hepatic insulin resistance, oxidative stress, and inflammation, could be potentially helpful to individuals with IFG and IFG/IGT to improve fasting glucose homeostasis [39,52,57]. On the other hand, plant extracts possessing mechanisms that facilitate postprandial glycemic control include inhibiting hepatic gluconeogenesis, suppressing glucagon release, enhancing the incretin effect, delaying carbohydrate digestion via inhibiting α-amylase and α-glucosidase, and slowing glucose absorption and uptake via inhibiting sodium-dependent glucose co-transporter-1 (SGLT1) and sodium-independent glucose transporter-2 (GLUT2) could potentially be utilized for individuals with IGT or IFG/IGT [40,45,57,58,59].
The question is whether plant extracts could emulate how these pharmacological agents are being categorized for a more effective, targeted clinical outcome for individuals in each prediabetes subgroup. A deeper understanding of the impact of plant extract interventions on prediabetes subgroups could enable the development of more targeted treatment strategies, with greater potential for slowing or stopping the development of T2DM.
In order to obtain results that elucidate the impact of interventions on individuals with varying degrees of dysglycemia [10,60,61], stratification based on the different glycemic profiles such as the prediabetes subgroups within the cohort is important. This will enable more specific identification of interventions appropriate for those having worsening glycemic profiles [62,63,64,65].
The present review therefore aims to (1) investigate human clinical trials that have been conducted to examine the impact of plant extracts on glycemic responses in individuals with prediabetes, and to (2) examine the effectiveness of each plant extract intervention in the prediabetes subgroups.

2. Human Clinical Trials Examining Effect of Plant Extracts on Glycemic Responses in the Prediabetes Cohort

Acute and chronic human clinical trials on plant extracts and involving participants with prediabetes were considered based on the ADA definition for prediabetes: IFG (FBG of 100–125 mg/dL and/or 2hPG < 140 mg/dL), IGT (2hPG of 140–199 mg/dL and/or FBG < 100 mg/dL) and IFG/IGT (FBG of 100–125 mg/dL and 2hPG of 140–199 mg/dL) [24].
Studies that included at least two glycemic measurement outcomes, such as fasting glycemic indices FBG, fasting insulin (FI), fasting C-peptide (FCP), and homeostasis model assessment-insulin resistance (HOMA-IR), and postprandial glycemic indices PG, PI, postprandial C-peptide (PCP), and glycated hemoglobin A1c (HbA1c), were considered. Only those published in English were included.
Studies that have incorporated other administered therapies, such as lifestyle modifications (e.g., physical activity) or concomitant glucose-lowering medications, or that involved fruit-based extracts, spices and traditional Chinese medicine, were beyond the scope of this review and therefore excluded.
Eleven RCT studies including one randomized, uncontrolled, parallel study covering eight different plant extracts and their impact on glycemic responses in prediabetes were identified for this review (Table 1). Two of the identified studies were acute studies and the rest, chronic studies of intervention duration ranging from four weeks to 12 weeks.
Plant extracts examined were Artemisia princeps Pampanini (Sajabalssuk) [66,67], Elaeis guineensis leaf [68], Ficus deltoidea leaf [68], soy (Glycine max (L.) Merrill) leaf [69,70], white mulberry (Morus alba Linn.) leaf [71,72,73,74], persimmon (Diospyros kaki) leaf [75], Citrus junos Tanaka peel [76], and Acacia. Mearnsii bark [77].
Ten trials involved participants with prediabetes having IFG. One trial recruited participants with prediabetes having IGT. Three trials recruited participants with prediabetes having combined IFG/IGT. All plant extracts examined were able to elicit certain significant improvement in either fasting glycemic measures such as FBG, FI, FCP and HOMA-IR, or postprandial glycemic responses such as PG, PI, PCP, as well as HbA1c in participants with prediabetes, except Ficus deltoidea leaf.
Table
Table 1. Human clinical trials involving plant extracts and their hypoglycemic impact in participants with prediabetes.
Table 1. Human clinical trials involving plant extracts and their hypoglycemic impact in participants with prediabetes.
Plant ExtractStudy DesignTotal Participant Analyzed and Gender
N (Male:Female)		Treatment DoseDurationGlycemic MeasurementsFindingsAdverse Events Reference
Sajabalssuk (Artemisia princeps Pampanini)RCT, parallel studyPrediabetes IFG
99 (42:57)		Placebo, positive control or 3000 mg/day9 weeksFBG, FI, HOMA-IR, HbA1c, lipid profile (TG, TC, HDL, non-HDL, HTR, AI and PL), SBP, DBP, BMI, WHR, BFP, ALT and ASTSignificant reduction in FBG and HbA1c compared to positive control, placebo and baseline.
Significant reduction in HOMA-IR compared to placebo but not to positive control or baseline.
No significant change in FI compared to positive control, placebo and baseline.
Significant increase in HDL and decrease in non-HDL compared to positive control, placebo and baseline.
Significant reduction in TC compared to positive control and baseline but not placebo.
No significant changes in TG, HTR, AI, PL, SBP and DBP compared to positive control, placebo and baseline.
No significant changes in BMI, WHR, BFP, ALT and AST compared to positive control, placebo and baseline.		Nil[66]
Sajabalssuk (Artemisia princeps Pampanini)RCT, parallel studyPrediabetes IFG and borderline diabetic
80 (51:29)		Placebo or positive control8 weeksFBG, FI, FCP, HOMA-IR, glucagon, HbA1c, FFA, ALT, AST, SBP and DBPSignificant reduction in FBG and HbA1c with both doses compared to baseline.
No significant changes in FI, FCP, HOMA-IR, glucagon and DBP with both doses compared to baseline.
Significant reduction in FFA and SBP with higher dose (4000 mg/day) compared to baseline.
Significant reduction in AST with both doses compared to baseline and a significant reduction in AST with lower dose (2000 mg/day) compared to positive control, but no significant change in ALT with both doses compared to baseline.		Nil[67]
2000 mg/day
4000 mg/day
Elaeis guineensis leafRandomized, parallel studyPrediabetes IFG
28 (gender not specified)		500 mg/day8 weeksFBG, FI, insulin sensitivity (%), HOMA-IR, PG AUC, PI AUC, BW and WCSignificant reduction in FBG, FI, insulin sensitivity (%) and WC compared to baseline, but no significant changes in HOMA-IR, PG AUC, PI AUC and BW compared to baseline.Light-headedness (n = 1)[68]
1000 mg/daySignificant reduction in PG AUC, PI AUC and WC compared to baseline but no significant changes to FBG, FI, HOMA-IR, insulin sensitivity (%) and BW compared to baseline.
Ficus deltoidea leafRandomized, parallel study1000 mg/dayNo significant changes observed.
Soy (Glycine max (L.) Merrill) leafRCT, parallel studyOverweight and prediabetes IFG
30 (16:14)		Placebo or 2000 mg/day12 weeksFBG, FI, HOMA-IR, HbA1c, BW, BMI, WC, WHR, BFP, lipid profile (TG, TC, HDL, LDL, HTR, and AI), ALT, AST, SBP and DBPSignificant reduction in FBG, HOMA-IR, HbA1c, WC, BFP, TG, AI, ALT and AST compared to placebo but not when compared to baseline.
Significant increase in HDL and HTR compared to placebo but not when compared to baseline.
No significant changes in FI, BW, BMI, WHR, TC, LDL, SBP and DBP compared to placebo and baseline.		Nil[69]
Pterocarpan-high Soy (Glycine max (L.) Merrill) leafRCT, parallel studyOverweight and obese, with borderline metabolic syndrome and prediabetes IFG
49 (11:38)		Placebo or 2000 mg/day12 weeksFBG, FI, HOMA-IR, HbA1c, BW, BMI, BFP, WHR, lipid profile (TG, FFA, TC, HDL, non-HDL, LDL, and AI), SBP, DBP, PAI-1, TNF-α, IL-6, MCP-1, adiponectin, and leptin, AST and ALTSignificant reduction in HOMA-IR and HbA1c compared to placebo and baseline.
Significant reduction in FBG, FI, TC and SBP compared to baseline but not when compared to placebo.
No significant changes to BW, BMI, BFP, WHR, DBP, AST and ALT compared to placebo and baseline.
No significant changes to lipid profile except significant reductions in FFA and non-HDL compared to placebo and baseline.
No significant changes to plasma adipokine and cytokine levels except significant reductions in PAI-1 and TNF-α compared to placebo and baseline, and significant reduction in IL-6 compared to baseline.		Nil[70]
White mulberry (Morus alba Linn.) leaf and white kidney bean extractRCT, parallel studyPrediabetes, IFG
65 (25:40)		1500 mg (500 mg mulberry extract with 10% DNJ, 1000 mg white kidney bean extract)AcutePG iAUC, PI iAUC, PCP iAUCSignificant reduction in PG iAUC, PI iAUC and PCP iAUC compared to control group in the acute study.Not reported[74]
4500 mg/day 4 weeksNo significant changes to PG iAUC, PI iAUC, PCP iAUC HOMA-IR, HbA1c, and GSP compared to control group in the chronic study
White mulberry (Morus alba Linn.) leaf and onion extractRCT, parallel studyPrediabetes
IFG
46 (5:41)		Placebo or
cooked rice coated with extract (8.8 mg DNJ)		AcutePG and PG AUCSignificant reduction in PG and PG AUC compared to placebo.Not reported[71]
White mulberry (Morus alba Linn.) leafRCT, parallel studyPrediabetes IFG
65 (43:22)		Placebo or extract with 6 mg DNJ12 weeksFBG, FI, GA, 1,5AG, HbA1cSignificant reduction in HbA1c from week 4 and GA from week 8 compared to baseline, but not when compared to placebo.
No significant changes in FBG and FI compared to baseline and placebo.
Significant increase in 1,5 AG from week 4, 8 and 12 compared to baseline, and overall significant increase compared to placebo.		Nil[72]
White mulberry (Morus alba Linn.) leafRCT, parallel studyPrediabetes IFG
38 (15:23)		Placebo or 5000 mg/day
(18 mg DNJ)		4 weeksPG and PG iAUC, PI and PI iAUC, PCP and PCP iAUC, ALT and ASTSignificant reduction in PG and PI only at 30 min compared to placebo.
Significant reduction in PCP at 30 and 60 min compared to placebo.
No significant changes in PG iAUC, PCP iAUC, ALT and AST but only PI iAUC was significantly lower than placebo.		Nil[73]
Persimmon (Diospyros kaki) leafRCT, parallel studyPrediabetes IGT
68 (gender not specified)		Placebo or 2000 mg/day8 weeksPGSignificant reduction in PG compared to placebo.Not reported[75]
Citrus junos Tanaka peelRCT, crossover studyPrediabetes
IFG/IGT
35 (gender not specified)		Placebo, or 4250 mg/day8 weeksFBG, FI, FCP, PG, HOMA-IRSignificant reduction in FBG, FI and HOMA-IR compared to placebo but not when compared to baseline.
No significant change in PG compared to placebo or baseline.
No significant change in FCP when compared to placebo but significant reduction in FCP when compared to baseline.		Nil[76]
Acacia. Mearnsii barkRCT, parallel studyPrediabetes, IFG/IGT
34 (26:8)		Placebo, or 250 mg/day8 weeksFBG, FI, HOMA-IR, PG and PG AUC and PI and PI AUC and HbA1cSignificant reduction in PG at 90 min and PI at 90 and 120 min compared to baseline.
Significant reduction in PG at 120 min and PI at 90 min after 8 weeks compared to placebo.
No significant changes in PG AUC and PI AUC compared to placebo but a significant reduction compared to baseline after 8 weeks.
No significant changes in FBG, FI, HOMA-IR and HbA1c after 8 weeks compared to placebo and baseline.		Nil[77]
White mulberry (Morus alba Linn.) leafRCT, crossover studyPrediabetes IFG/IGT
10 (8:2)		PlaceboAcutePG and PINot applicable.Nil[72]
Extract with 3 mg DNJNo significant change in PG compared to placebo but a significant reduction in PI at 30 min compared to placebo.
Extract with 6 mg DNJSignificant reduction in PG at 30 min and significant reduction in PI at 30 min compared to placebo.
Extract with 9 mg DNJSignificant reduction in PG at 30 min and significant reduction in PI at 30 min compared to placebo.
ALT: alanine aminotransferase; AI: atherogenic index; AST: aspartate aminotransferase; BFP: body fat percentage; BMI: body mass index; BW: body weight; DBP: diastolic blood pressure; DNJ: 1-deoxynojirimycin; FBG: fasting blood glucose; FCP: fasting C-peptide; FFA: free fatty acid; FI: fasting insulin; GA: glycated albumin; GSP: glycated serum protein; HbA1c: glycated hemoglobin A1c; HDL: high-density lipoprotein cholesterol; HOMA-IR: homeostasis model assessment-insulin resistance; HTR: high-density lipoprotein cholesterol (HDL) to total cholesterol (TC) ratio; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; IFG/IGT: combined impaired fasting glucose and impaired glucose tolerance; IL-6: interleukin-6; LDL: low-density lipoprotein cholesterol; MCP-1: monocyte chemotactic protein-1; PAI-1: plasminogen activator inhibitor-1; PCP: postprandial C-peptide; PCP iAUC: incremental area under the curve of postprandial C-peptide; PG: postprandial glucose; PG AUC: area under the curve of postprandial glucose; PG iAUC: incremental area under the curve of postprandial glucose; PI: postprandial insulin; PI AUC: area under the curve of postprandial insulin; PI iAUC: incremental area under the curve of postprandial insulin; PL: phospholipid; SBP: systolic blood pressure; TC: total cholesterol; TG: triglyceride; TNF-α: tumor necrosis factor-α; WC: waist circumference; WHR: waist-hip ratio; 1,5AG: 1,5-anhydroglucitol.

3. Effectiveness of Plant Extracts on Glycemic Responses in the Prediabetes Subgroups

Table 2 summarizes the significant changes in glycemic clinical outcomes of the interventions with the plant extracts based on each subgroup.

3.1. Hypoglycemic Effects of Plant Extracts on Impaired Fasting Glucose (IFG)

3.1.1. Artemisia princeps Pampanini

Artemisia princeps Pampanini (A. princeps) belongs to one of the 500 plants under the genus Artemisia, and is commonly found in China, Korea and Japan [78,79], and has been used to treat diabetes [80,81]. High concentrations of antioxidants and flavonoids such as eupatilin and jaceosidin have likely contributed to its anti-diabetic effects [78,79,82,83]. A. princeps has been shown to be well tolerated with no reported side effects nor any adverse effects on the liver at a concentration of 3000 mg/day for nine weeks [66], and up to 4000 mg/day for eight weeks in humans with IFG [67].
The Korean A. princeps or Sajabalssuk extract (3000 mg/day) has also been examined in a prediabetes cohort for its glucose-lowering effects [66]. There were significant reductions in FBG compared to placebo and positive control after nine weeks of intervention, thus restoring normal FBG levels. Sajabalssuk extract also significantly decreased HbA1c and insulin resistance (HOMA-IR) with improvement in high-density lipoprotein (HDL) cholesterol level (p < 0.05) compared to control [66].
An earlier study conducted by the same group also showed significant reductions in FBG and HbA1c at both doses (2000 and 4000 mg/day) in participants with IFG and borderline T2DM (FBG 123.3 ± 5.7–125.8 ± 6.1 mg/dL) compared to participant baseline after eight weeks of intervention [67]. High dose (4000 mg/day) of the extract was also able to significantly decrease plasma free fatty acid (FFA) levels (p < 0.05) compared to participant baseline.
These chronic studies demonstrated that A. princeps (Sajabalssuk) extract was able to improve fasting glycemic responses in IFG participants. The clinical outcomes were supported by mechanistic studies done on animal models that elucidated reduced hepatic gluconeogenesis by A. princeps by up-regulating hepatic glucokinase (GK) and down-regulating glucose 6-phosphatase (G6Pase) activity [78], as well as phosphoenol-pyruvate carboxykinase (PEPCK), whist not having an effect on α-glucosidase inhibition [84].

3.1.2. Elaeis guineensis Leaf

Elaeis guineensis (E. guineensis) leaf comes from oil palm and is commonly found in Malaysia, Thailand, Indonesia, Africa and South America [68,85,86]. It has been known to contain high levels of antioxidant activity rich in phenolic compounds such as catechin, apigenin and luteolin [87,88], and in vitro and animal studies have elucidated E. guineensis to be beneficial for metabolic syndrome and T2DM by promoting vascular relaxation and reducing inflammation and lipid oxidation [85,87,89,90,91].
Kalman and group investigated the hypoglycemic effects of E. guineensis leaf extract at two doses (500 and 1000 mg) in participants with IFG for eight weeks [68]. E. guineensis leaf extract at lower dose (500 mg) was able to significantly improve FBG (p = 0.02), fasting insulin (FI) (p = 0.04), and HOMA-IR (p = 0.03) compared to participant baseline levels. In contrast, the higher dose (1000 mg) was only able to significantly improve PG and PI responses (p = 0.046 and p = 0.006, respectively) compared to participant baseline levels. Having no placebo group was a limitation of the study. The improvement in glycemia in participants may be attributed to the reduction in oxidative stress [85].
Due to the paucity of clinical data regarding E. guineensis leaf, more research is required to investigate the glucose-lowering potential of E. guineensis leaf in people with prediabetes.

3.1.3. Ficus deltoidea Leaf

Ficus deltoidea (F. deltoidea) belongs to the Moraceae plant family and is native to the Malayan Archipelago [92]. It is high in phenolic content such as flavan-3-ol monomers, catechin and afzelechin and antioxidant activity [93,94]. In the past decade in vitro and animal studies have shown F. deltoidea as a potential anti-diabetic treatment owing to its glucose-lowering effects and its ability to stimulate insulinotropic activity and glucose uptake [92,95,96,97,98,99,100]. F. deltoidea leaves have been toxicologically examined [96,97,100,101] and generally considered to be safe for human consumption [102].
There was only one 8-week prospective, randomized, double-blind, parallel study conducted investigating the impact of a single dose of F. deltoidea leaf extract (1000 mg) on individuals with IFG [68]. No significant changes in fasting and postprandial glucose and insulin responses were observed. Nonetheless, a number of in vitro and animal studies have elucidated that F. deltoidea leaf extract was able to suppress gluconeogenesis and stimulate insulin secretion to improve fasting glycemia, [95,103,104,105] and exhibited inhibitory action on α-amylase and α-glucosidase activities [99,100,106]. This therefore warrants further study investigating the potential impact of different doses on glycemic in humans.

3.1.4. Soy (Glycine max (L.) Merrill) Leaf

Soy (Glycine max (L.) Merrill) leaf is common in Korea and Japan [107,108,109]. Soy leaf is rich in polyphenols such as kaempferol glycosides, coumestrol and pterocarpan [108,109,110,111], which have been shown to contain anti-diabetic properties [108,111,112]. Soy leaves at a concentration of 2000 mg/day for 10 weeks in overweight individuals has been shown to have no effects on the liver or other adverse side effects [113].
Choi and colleagues (2014) showed that consuming soy leaf extract (2000 mg/day) for 12 weeks led to significant reductions in baseline-adjusted FBG, HOMA-IR, HbA1c and lipid profile in overweight participants with IFG compared to placebo (p < 0.05) [69]. This finding was in agreement with another RCT investigating the impact of pterocarpan-high soy leaf extract (2000 mg/day) for 12 weeks on glucose tolerance in overweight and obese IFG participants with borderline metabolic syndrome [70]. Significant reductions in HbA1c, HOMA-IR, FFA and non-HDL cholesterol were observed in the intervention compared to control group. FBG and FI were also reduced after intervention compared to participant baseline.
The clinical outcomes suggest that that the intervention with soy leaf extract could potentially benefit those with IFG as seen in the improvements in fasting glycemic indices (FBG and HOMA-IR), with the addition of improved long-term glycemic measurement, HbA1c and improved lipid profile. Animal studies have elucidated that the underlying mechanisms observed in the glycemic improvements might be due to the regulation of β-cell proliferation, suppression of hepatic gluconeogenesis and lipid accumulation, and stimulation of insulin [107,109,114,115].

3.1.5. White mulberry Leaf

White mulberry (Morus alba Linn.) leaf comes from the mulberry tree belonging to the family Moraceae, native to Korea, Japan and China but also widely cultivated in other parts in Europe [116]. Mulberry leaf has been extensively studied and reviews have been written regarding its hypoglycemic effects, in particular, its inhibition on α-glucosidase [116,117,118].
A variety of polyphenols, such as quercetin, chlorogenic acid and rutin, and nitrogen-containing glucose analog 1-deoxynojirimycin (DNJ) contained in mulberry leaf, contribute to the hypoglycemic effects observed [119,120,121,122,123,124]. DNJ has been shown as a strong α-glucosidase inhibitor due to its size and structural similarity to glucose [125,126] and has been used to standardize mulberry leaf extracts, with other phenolic components in the leaf contributing to its combined inhibitory action [71,119,125,127,128,129,130].
Mulberry leaf extract has also been tested toxicologically in humans. A concentration of 3600 mg/day of mulberry leaf extract for 38 days also did not show any adverse effects in healthy participants [131]. Another study supported the mulberry leaf extract (3000 mg/day for three months) to be safe for consumption for diabetic participants [132].
Considerable human studies have further elucidated the hypoglycemic effects of mulberry leaf extract in healthy participants, with fewer studies on prediabetes and T2DM [71,72,73,129,131,132,133,134,135,136,137,138,139]. Liu and colleagues (2020) investigated the acute hypoglycemic effects of an extract mixture of mulberry leaf and white kidney bean in participants with IFG [74]. A significant reduction in glycemic responses of incremental area under the curve (iAUC) such as PG iAUC, PI iAUC and PCP iAUC was observed compared to control. However, the glycemic improvements could not be solely attributed to mulberry leaf extract as the intervention mixture also contained white kidney bean extract. In contrast, the same study did not observe similar improvements in a 4-week chronic trial [74].
Hwang and co-workers (2016) investigated the impact of 50% ethanolic extract of mulberry leaf (20% in mixture) with onion extract coated on 75 g cooked rice (11.77 ± 1.67 mg DNJ/100 g rice) and observed an improvement in PG (p < 0.05) and postprandial glucose area under the curve (PG AUC) (p < 0.001) after an oral glucose tolerance test (OGTT) (75 g cooked rice) in participants with IFG compared to the placebo group [71]. The addition of a water extract of onion in the intervention mixture might have contributed to the glycemic improvements but no further information was provided in the study regarding its impact on glycemia [71].
Asai and co-workers (2011) observed a significant increase in serum 1,5-anhydroglucitol (1,5-AG) concentration, an indication of reduced postprandial hyperglycemic spikes, in participants with IFG after consuming mulberry leaf (6 mg DNJ) for 12 weeks (p < 0.001) in comparison to control [72]. However, no significant changes were found in FBG, FI, HbA1c and glycated albumin (GA) concentrations compared to the placebo, but HbA1c was significantly reduced from 4-week onwards within the intervention group compared to participant baseline (6.0 ± 0.4% vs. 5.9 ± 0.3%, p < 0.05).
Kim and colleagues (2014) investigated the impact of 4-week mulberry leaf extract (5000 mg/day, 0.36% or 18 mg DNJ) in IFG participants and demonstrated significant reductions in PG, PI and postprandial C-peptide (PCP) especially at 30 min post-load compared to placebo [73]. However, no significant changes were found in FBG, FI and HbA1c compared to the placebo.
Studies of mulberry leaf extract on healthy participants and individuals with prediabetes or T2DM have consistently shown non-significant changes in FBG and FI [72,73,131,132,138,139]. This may suggest that mulberry leaf extract, which is functionally similar to acarbose, may be more beneficial for individuals with IGT due to its inhibitory action on digestive enzyme (α-glucosidase) post-load.
Future studies of mulberry leaf could ascertain the inhibition of α-glucosidase in participants with prediabetes using hydrogen tests and starch 13C breath test that have been conducted in healthy and T2DM participants to indicate carbohydrate indigestion [134,135,136,139].

3.2. Hypoglycemic Effects of Plant Extracts on Impaired Glucose Tolerance (IGT)

Persimmon Leaf

Persimmon (Diospyros kaki) leaf belongs to the family of Ebenaceae and has been traditionally used in Japan, South Korea and China as a folk medicine [140]. The persimmon leaf has shown to possess anti-oxidative properties mediated by its rich phenolic concentration [141,142,143]. Phenolic compounds such as triterpenoids isolated from persimmon leaf have been shown to exhibit anti-diabetic properties via inhibiting protein tyrosine phosphatase 1B (PTP1B) activity (>80% inhibition at 30 μg/mL) [144]. Vomifoliol, which is found in persimmon leaf, has been identified as a potent a α-glucosidase inhibitor and an enhancer of peripheral glucose utilization [145].
Khan and colleagues (2017) demonstrated consuming 2000 mg of persimmon leaf extract for eight weeks in IGT participants led to significant PG reduction in the intervention group compared to control (p = 0.029) [75]. Within the same study, samples of saliva, urine and serum collected from a subgroup of five participants with combined IFG/IGT were analyzed for potential protein markers of persimmon leaf treatment. Outcomes showed Tamm–Horsfall protein, uromodulin, SPARC-like protein 1 precursor (SPARCL1) and Complement C7 were down-regulated while Ezrin was up-regulated, indicating ameliorating effects of persimmon leaf on glycemia [75].
In vitro and animal studies on persimmon leaf have elucidated the mechanistic action of α-amylase and α-glucosidase inhibition [146,147,148], which might have led to the PG reduction observed in the IGT participants due to reduced carbohydrate digestion [75]. Another mechanism of action demonstrated by persimmon leaf might be the inhibition Na+/glucose co-transporter (SGLT1) as the final stage of glucose absorption, as demonstrated by significant reductions in PG in rats after glucose loading [148].

3.3. Hypoglycemic Effects of Plant Extracts on Combined Impaired Fasting Glucose and Impaired Glucose Tolerance (IFG/IGT)

3.3.1. Citrus junos Tanaka Peel

The Citrus junos Tanaka (C. junos) fruit, also known as yuja or yuzu, is a yellow citrus fruit easily obtainable in Japan, Korea and China, and contains a high concentration of phenolic content and vitamin C compared to the flesh [149,150,151,152,153]. The major phenolic compounds hesperidin and naringin [149], which have been known for improving glycemia [154].
Hwang and co-workers (2015) determined the impact of C. junos peel extract on glycemic responses in participants with combined IFG/IGT [76]. After eight weeks of intervention (4250 mg/day), the intervention group showed significantly reduced FBG (p = 0.049), FI (p = 0.038) and HOMA-IR (p = 0.019) compared to the placebo group. C-peptide in the intervention group was also marginally reduced (p = 0.057) but no significant improvement in PG compared to placebo. The study showed that C. junos peel could only improve fasting glycemic indices in combined IFG/IGT participants [76]. The hypoglycemic mechanism might be attributed to increased glucose uptake via increased insulin action in the peripheral tissues [152].

3.3.2. Acacia. mearnsii bark

Acacia. mearnsii (A.mearnsii) bark from the black wattle tree of the legume family has been gaining attention for its anti-diabetic effects [155,156]. Its anti-diabetic potential may be attributed to the abundant antioxidants and proanthocyanidins, such as catechin-like flavan-3-ols, and in particular, robinetinidol and fisetinidol present in the bark [155].
An 8-week consumption of A. mearnsii bark (1000 mg/day) led to significant reduction in PG at 120 min (p = 0.013) and PI at 90 min (p = 0.032) compared to placebo in participants with combined IFG/IGT [77]. There was also a significant reduction in glucose at 90 min (p = 0.014), and a reduction in insulin concentration at 90 and 120 min (p = 0.002 and p = 0.004, respectively), with an overall reduction in PG AUC and postprandial insulin area under the curve (PI AUC) (p = 0.018 and p = 0.009, respectively) within the intervention group. However, there was no change in fasting glycemic measures such as FBG, FI, HOMA-IR and HbA1c compared to the placebo. Mechanistic in vitro studies indicate that the postprandial hypoglycemic effects of A. mearnsii bark could be due to inhibition of the digestive enzymes α-amylase and α-glucosidase [155,156,157,158,159,160,161]. This study suggests that A. mearnsii bark preferentially improved postprandial glycemic responses instead of fasting glycemic responses in IFG/IGT participants.

3.3.3. White mulberry Leaf

The mulberry leaf extract was also examined in participants with combined IFG/IGT by Asai and co-workers (2011) [72]. They found that the extract (3, 6 or 9 mg DNJ) significantly reduced acute PG responses in a dose-dependent manner compared to the placebo (p = 0.006). This indicates that mulberry leaf may preferentially improve postprandial glycemic responses in individuals with IFG/IGT. As discussed earlier in Section 3.1.5, mulberry leaf extract was shown to improve postprandial glycemic responses in IFG participants as well.

4. Does Each Prediabetes Subgroup Benefit from Different Plant Extracts?

Phenolic-rich plant extracts have been known to improve glucose regulation in individuals with prediabetes; however, not all plant extracts may benefit both fasting and postprandial hyperglycemia.
Table 2 shows how the different plant extracts can be more appropriately used for individuals with IFG or IGT, based on whether they could improve fasting or postprandial glycemic responses, respectively.
Plant extracts that were able to demonstrate improvements in fasting glycemic indices such as FBG, FI and HOMA-IR were categorized as being useful for IFG. In contrast, plant extracts that demonstrated to improve postprandial glycemic indices such as PG and PI were grouped as being helpful for IGT. This is likely due to the different phenolic structures of each plant extract that enables varying kinds of hypoglycemic mechanisms of action [39,44,162,163].
Table 3 summarizes how the plant extracts that have been discussed can help individuals with IFG or IGT. Individuals with IFG/IGT are likely to benefit from both categories of glycemic improvement.

5. Strengths and Limitations

The merits of the present review were the inclusion of a range of human clinical trials investigating plant extracts with promising hypoglycemic potential in individuals with prediabetes, and examination of the effectiveness of each plant extract intervention on the three prediabetes subgroups.
However, the review is not without limitations. The review has included single dose studies with some studies having only small sample sizes. More human studies are necessary to ascertain the hypoglycemic impact of the plant extracts in people with prediabetes.
Most of the studies included did not clearly differentiate between the subgroups of prediabetes during recruitment. For example, nine studies that were included have only measured FBG to recruit participants with IFG; however, these participants might also have IGT, but participant baseline PG during screening was not measured. This limitation highlights the importance of measuring both fasting and postprandial indices during screening visits in future studies and for the purpose of classifying participants into the different prediabetes subgroups.
Additionally, owing to the lower reproducibility with current measurements using FBG and 2hPG, caution should be exercised when classifying individuals into IFG or IGT based on a single test [11,164]. However, the cost and practicality may need to be considered.
Furthermore, studies have not included both fasting and postprandial measurements after intervention. For example, the study of persimmon leaf extract only measured postprandial glycemic response such as PG in IGT participants. On the other hand, studies of Sajabalssuk and soybean leaf extract only measured fasting glycemic responses such as FBG and FI without investigating postprandial glycemic measures in IFG participants. Therefore, the extensive impact of the plant extracts on both fasting and postprandial glycemia could not be known.
Most of the studies included in this review did not take into account possible changes in β-cell function, insulin sensitivity and changes to lipid metabolism. This is important because the preservation or restoration of β-cell function is pivotal in slowing or halting the progression of prediabetes into T2DM [165,166,167,168]. Dyslipidaemia often occurs in prediabetes and may gradually impair insulin signaling and function, and therefore is an important endpoint measurement in interventions [169].

6. Conclusions

This review has explored a new perspective in viewing how nutritional interventions could cater to the different prediabetes subgroups of IFG, IGT and IFG/IGT. Among these studies, interventions with plant extracts have elucidated preferential improvements of glycemic measurements in either the fasting or postprandial state, or both, which can become beneficial for IFG, IGT or IFG/IGT, respectively. Moreover, individuals with IFG/IGT are likely to benefit from plant extracts providing either fasting or postprandial glycemic improvements. Future research on prediabetes should look into obtaining both fasting and postprandial measurements at screening and during intervention to enable participant classification into the distinct subgroups and to determine the respective impact of plant extracts on fasting and postprandial glycemia. This could allow for more tailored treatments with optimal glycemic outcomes that are specific for each of the prediabetes subgroups. Furthermore, the plant extracts discussed in this review warrant further study into their pharmacokinetic and pharmacodynamic properties along with their safety profiles for higher doses and chronic use. This will ensure the plant extracts are better characterized and standardized for use as adjuncts for prediabetes treatment.

Author Contributions

Writing—Original Draft Preparation, W.X.J.L.; Writing—Review & Editing, W.X.J.L., C.S.G., P.v.H., L.C. and R.A.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. International Diabetes Federation. IDF Diabetes Atlas, 9th ed.; IDF: Brussels, Belgium, 2019. [Google Scholar]
  2. Stratton, I.M.; Adler, A.I.; Neil, H.A.W.; Matthews, D.R.; Manley, S.E.; Cull, C.A.; Hadden, D.; Turner, R.C.; Holman, R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000, 321, 405–412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Bandeira, S.D.M.; Da Fonseca, L.J.S.; Guedes, G.D.S.; Rabelo, L.A.; Goulart, M.O.F.; Vasconcelos, S.M.L. Oxidative Stress as an Underlying Contributor in the Development of Chronic Complications in Diabetes Mellitus. Int. J. Mol. Sci. 2013, 14, 3265–3284. [Google Scholar] [CrossRef] [PubMed]
  4. Ogurtsova, K.; Da Rocha Fernandes, J.D.; Huang, Y.; Linnenkamp, U.; Guariguata, L.; Cho, N.H.; Cavan, D.; Shaw, J.E.; Makaroff, L.E. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res. Clin. Pract. 2017, 128, 40–50. [Google Scholar] [CrossRef] [Green Version]
  5. Bansal, N. Prediabetes diagnosis and treatment: A review. World J. Diabetes 2015, 6, 296–303. [Google Scholar] [CrossRef] [PubMed]
  6. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus; Seino, Y.; Nanjo, K.; Tajima, N.; Kadowaki, T.; Kashiwagi, A.; Araki, E.; Ito, C.; Inagaki, N.; Iwamoto, Y.; et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J. Diabetes Investig. 2010, 1, 212–228. [Google Scholar] [CrossRef] [Green Version]
  7. Gerstein, H.C.; Santaguida, P.; Raina, P.; Morrison, K.; Balion, C.; Hunt, D.; Yazdi, H.; Booker, L. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies. Diabetes Res. Clin. Pr. 2007, 78, 305–312. [Google Scholar] [CrossRef] [PubMed]
  8. Tabák, A.G.; Herder, C.; Rathmann, W.; Brunner, E.; Kivimaki, M. Prediabetes: A high-risk state for diabetes development. Lancet 2012, 379, 2279–2290. [Google Scholar] [CrossRef] [Green Version]
  9. Brannick, B.; Wynn, A.; Dagogo-Jack, S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp. Biol. Med. 2016, 241, 1323–1331. [Google Scholar] [CrossRef] [Green Version]
  10. Faerch, K.; Hulman, A.; Solomon, T. Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness. Curr. Diabetes Rev. 2015, 12, 30–41. [Google Scholar] [CrossRef] [PubMed]
  11. Echouffo-Tcheugui, J.B.; Kengne, A.P.; Ali, M. Issues in Defining the Burden of Prediabetes Globally. Curr. Diabetes Rep. 2018, 18, 105. [Google Scholar] [CrossRef]
  12. Færch, K.; Borch-Johnsen, K.; Holst, J.J.; Vaag, A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: Does it matter for prevention and treatment of type 2 diabetes? Diabetologia 2009, 52, 1714–1723. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. van Haeften, T.W.; Pimenta, W.; Mitrakou, A.; Korytkowski, M.; Jenssen, T.; Yki-Jarvinen, H.; Gerich, J.E. Disturbances in beta-cell function in impaired fasting glycemia. Diabetes 2002, 51, S265–S270. [Google Scholar] [CrossRef] [Green Version]
  14. Writing Committee; Unwin, N.; Shaw, J.; Zimmet, P.; Alberti, K.G.M.M. Impaired glucose tolerance and impaired fasting glycaemia: The current status on definition and intervention. Diabet. Med. 2002, 19, 708–723. [Google Scholar] [CrossRef] [PubMed]
  15. Tuomilehto, J.; Lindstrom, J.; Keinanen-Kiukaanniemie, S.; Hiltunen, L.; Kivela, S.L.; Gallus, G.; Garancini, M.P.; Schranz, A.; Bouter, L.M.; Dekker, J.M.; et al. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003, 26, 61–69. [Google Scholar]
  16. Shaw, J.E.; Zimmet, P.Z.; De Courten, M.; Dowse, G.K.; Chitson, P.; Gareeboo, H.; Hemraj, F.; Fareed, D.; Tuomilehto, J.; Alberti, K.G. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 1999, 22, 399–402. [Google Scholar] [CrossRef] [PubMed]
  17. Abdul-Ghani, M.A.; DeFronzo, R.A. Pathophysiology of prediabetes. Curr. Diabetes Rep. 2009, 9, 193–199. [Google Scholar] [CrossRef]
  18. DECODA Study Group. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 2003, 26, 1770–1780. [Google Scholar] [CrossRef] [Green Version]
  19. Kim, S.H.; Reaven, G.M. Isolated Impaired Fasting Glucose and Peripheral Insulin Sensitivity: Not a simple relationship. Diabetes Care 2007, 31, 347–352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Abdul-Ghani, M.A.; Jenkinson, C.P.; Richardson, D.K.; Tripathy, D.; DeFronzo, R.A. Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose Tolerance: Results From the Veterans Administration Genetic Epidemiology Study. Diabetes 2006, 55, 1430–1435. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Hanefeld, M.; Koehler, C.; Fuecker, K.; Henkel, E.; Schaper, F.; Temelkova-Kurktschiev, T. Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study. Diabetes Care 2003, 26, 868–874. [Google Scholar] [CrossRef] [Green Version]
  22. Abdul-Ghani, A.M.; Tripathy, D.; De Fronzo, R.A. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006, 29, 1130–1139. [Google Scholar] [CrossRef]
  23. Kanat, M.; Mari, A.; Norton, L.; Winnier, D.; DeFronzo, R.A.; Jenkinson, C.; Abdul-Ghani, M.A. Distinct beta-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance. Diabetes 2012, 61, 447–453. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Nathan, D.M.; Davidson, M.B.; DeFronzo, R.A.; Heine, R.J.; Henry, R.R.; Pratley, R.; Zinman, B. Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care. Diabetes Care 2007, 30, 753–759. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Færch, K.; Vaag, A.; Holst, J.J.; Glümer, C.; Pedersen, O.; Borch-Johnsen, K. Impaired fasting glycaemia vs impaired glucose tolerance: Similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 2008, 51, 853–861. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Festa, A.; D’Agostino, R.; Hanley, A.J.; Karter, A.J.; Saad, M.F.; Haffner, S.M. Differences in Insulin Resistance in Nondiabetic Subjects with Isolated Impaired Glucose Tolerance or Isolated Impaired Fasting Glucose. Diabetes 2004, 53, 1549–1555. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Meyer, C.; Pimenta, W.; Woerle, H.J.; Van Haeften, T.; Szoke, E.; Mitrakou, A.; Gerich, J. Different Mechanisms for Impaired Fasting Glucose and Impaired Postprandial Glucose Tolerance in Humans. Diabetes Care 2006, 29, 1909–1914. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Schianca, G.P.C.; Rossi, A.; Sainaghi, P.P.; Maduli, E.; Bartoli, E. The Significance of Impaired Fasting Glucose Versus Impaired Glucose Tolerance: Importance of insulin secretion and resistance. Diabetes Care 2003, 26, 1333–1337. [Google Scholar] [CrossRef] [Green Version]
  29. Weyer, C.; Bogardus, C.; Pratley, R.E. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999, 48, 2197–2203. [Google Scholar] [CrossRef] [PubMed]
  30. Wasada, T.; Kuroki, H.; Katsumori, K.; Arii, H.; Sato, A.; Aoki, K.; Jimba, S.; Hanai, G. Who are more insulin resistant, people with IFG or people with IGT? Diabetologia 2004, 47, 759–760. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Bock, G.; Chittilapilly, E.; Basu, R.; Toffolo, G.; Cobelli, C.; Chandramouli, V.; Landau, B.R.; Rizza, R.A. Contribution of Hepatic and Extrahepatic Insulin Resistance to the Pathogenesis of Impaired Fasting Glucose: Role of Increased Rates of Gluconeogenesis. Diabetes 2007, 56, 1703–1711. [Google Scholar] [CrossRef] [Green Version]
  32. Godsland, I.F.; Jeffs, J.A.R.; Johnston, D.G. Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 2004, 47, 1157–1166. [Google Scholar] [CrossRef] [Green Version]
  33. Kanat, M.; Norton, L.; Winnier, D.; Jenkinson, C.; DeFronzo, R.A.; Abdul-Ghani, M.A. Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose. Acta Diabetol. 2011, 48, 209–217. [Google Scholar] [CrossRef] [PubMed]
  34. Ahren, B.; Larsson, H. Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 2001, 44, 1998–2003. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Båvenholm, P.N.; Pigon, J.; Östenson, C.-G.; Efendic, S. Insulin Sensitivity of Suppression of Endogenous Glucose Production Is the Single Most Important Determinant of Glucose Tolerance. Diabetes 2001, 50, 1449–1454. [Google Scholar] [CrossRef] [Green Version]
  36. Richter, B.; Hemmingsen, B.; Metzendorf, M.-I.; Takwoingi, Y. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst. Rev. 2018, 10, CD012661. [Google Scholar] [CrossRef] [PubMed]
  37. Abdul-Ghani, M.; DeFronzo, R.A. Fasting Hyperglycemia Impairs Glucose- But Not Insulin-Mediated Suppression of Glucagon Secretion. J. Clin. Endocrinol. Metab. 2007, 92, 1778–1784. [Google Scholar] [CrossRef] [Green Version]
  38. Williamson, G. The role of polyphenols in modern nutrition. Nutr. Bull. 2017, 42, 226–235. [Google Scholar] [CrossRef] [PubMed]
  39. Kim, Y.; Keogh, J.B.; Clifton, P.M. Polyphenols and Glycemic Control. Nutrients 2016, 8, 17. [Google Scholar] [CrossRef] [PubMed]
  40. Williamson, G. Possible effects of dietary polyphenols on sugar absorption and digestion. Mol. Nutr. Food Res. 2013, 57, 48–57. [Google Scholar] [CrossRef]
  41. Cheynier, V. Polyphenols in foods are more complex than often thought. Am. J. Clin. Nutr. 2005, 81, 223S–229S. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Russo, B.; Picconi, F.; Malandrucco, I.; Frontoni, S. Flavonoids and Insulin-Resistance: From Molecular Evidences to Clinical Trials. Int. J. Mol. Sci. 2019, 20, 2061. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Burton-Freeman, B.; Brzeziński, M.; Park, E.; Sandhu, A.; Xiao, D.; Edirisinghe, I. A Selective Role of Dietary Anthocyanins and Flavan-3-ols in Reducing the Risk of Type 2 Diabetes Mellitus: A Review of Recent Evidence. Nutrients 2019, 11, 841. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Cao, H.; Ou, J.; Chen, L.; Zhang, Y.; Szkudelski, T.; Delmas, D.; Daglia, M.; Xiao, J. Dietary polyphenols and type 2 diabetes: Human Study and Clinical Trial. Crit. Rev. Food Sci. Nutr. 2019, 59, 3371–3379. [Google Scholar] [CrossRef]
  45. Al-Ishaq, R.K.; Abotaleb, M.; Kubatka, P.; Kajo, K.; Büsselberg, D. Flavonoids and Their Anti-Diabetic Effects: Cellular Mechanisms and Effects to Improve Blood Sugar Levels. Biomolecules 2019, 9, 430. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Zhao, C.; Yang, C.; Wai, S.T.C.; Zhang, Y.; Portillo, M.P.; Paoli, P.; Wu, Y.; Cheang, W.S.; Liu, B.; Carpéné, C.; et al. Regulation of glucose metabolism by bioactive phytochemicals for the management of type 2 diabetes mellitus. Crit. Rev. Food Sci. Nutr. 2018, 59, 830–847. [Google Scholar] [CrossRef]
  47. Bahadoran, Z.; Mirmiran, P.; Azizi, F. Dietary polyphenols as potential nutraceuticals in management of diabetes: A review. J. Diabetes Metab. Disord. 2013, 12, 43. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Scalbert, A.; Manach, C.; Morand, C.; Rémésy, C.; Jiménez, L. Dietary Polyphenols and the Prevention of Diseases. Crit. Rev. Food Sci. Nutr. 2005, 45, 287–306. [Google Scholar] [CrossRef] [PubMed]
  49. Scalbert, A.; Johnson, I.; Saltmarsh, M. Polyphenols: Antioxidants and beyond. Am. J. Clin. Nutr. 2005, 81, 215S–217S. [Google Scholar] [CrossRef] [PubMed]
  50. Martel, F.; Monteiro, R.; Calhau, C. Effect of polyphenols on the intestinal and placental transport of some bioactive compounds. Nutr. Res. Rev. 2010, 23, 47–64. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Xiao, B.J.; Högger, P. Dietary polyphenols and type 2 diabetes: Current insights and future perspectives. Curr. Med. Chem. 2015, 22, 23–38. [Google Scholar] [CrossRef] [PubMed]
  52. Habtemariam, S.; Varghese, G.K. The antidiabetic therapeutic potential of dietary polyphenols. Curr. Pharm. Biotechnol. 2014, 15, 391–400. [Google Scholar] [CrossRef]
  53. Potenza, M.V.; Mechanick, J.I. The Metabolic Syndrome: Definition, Global Impact, and Pathophysiology. Nutr. Clin. Pract. 2009, 24, 560–577. [Google Scholar] [CrossRef]
  54. Tahrani, A.; Barnett, A.A.T.A.H.; Bailey, C.J. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2016, 12, 566–592. [Google Scholar] [CrossRef] [Green Version]
  55. Knowler, W.C.; Barrett-Connor, E.; Fowler, S.E.; Hamman, R.F.; Lachin, J.M.; Walker, E.A.; Nathan, D.M. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N. Engl. J. Med. 2002, 346, 393–403. [Google Scholar] [CrossRef] [PubMed]
  56. Hong, J.; Gui, M.H.; Gu, W.Q.; Zhang, Y.F.; Xu, M.; Chi, Z.N.; Zhang, Y.; Li, X.Y.; Wang, W.Q.; Ning, G. Differences in insulin resistance and pancreatic B-cell function in obese subjects with isolated impaired glucose tolerance and isolated impaired fasting glucose. Diabet. Med. 2008, 25, 73–79. [Google Scholar]
  57. Tanveer, A.; Akram, K.; Farooq, U.; Hayat, Z.; Shafi, A. Management of diabetic complications through fruit flavonoids as a natural remedy. Crit. Rev. Food Sci. Nutr. 2017, 57, 1411–1422. [Google Scholar] [CrossRef] [PubMed]
  58. Silva, B.; Oliveira, P.F.; Casal, S.; Alves, M.; Dias, T. Promising Potential of Dietary (Poly)Phenolic Compounds in the Prevention and Treatment of Diabetes Mellitus. Curr. Med. Chem. 2017, 24, 334–354. [Google Scholar] [CrossRef] [PubMed]
  59. Hanhineva, K.; Törrönen, R.; Bondia-Pons, I.; Pekkinen, J.; Kolehmainen, M.; Mykkänen, H.; Poutanen, K. Impact of Dietary Polyphenols on Carbohydrate Metabolism. Int. J. Mol. Sci. 2010, 11, 1365–1402. [Google Scholar] [CrossRef] [PubMed]
  60. Morris, C.; O’Grada, C.; Ryan, M.; Roche, H.; Gibney, M.J.; Gibney, E.R.; Brennan, L. Identification of Differential Responses to an Oral Glucose Tolerance Test in Healthy Adults. PLoS ONE 2013, 8, e72890. [Google Scholar] [CrossRef]
  61. Krishnan, S.; Newman, J.W.; Hembrooke, T.A.; Keim, N.L. Variation in metabolic responses to meal challenges differing in glycemic index in healthy women: Is it meaningful? Nutr. Metab. 2012, 9, 26. [Google Scholar] [CrossRef] [Green Version]
  62. Dagogo-Jack, S.; Askari, H.; Tykodi, G. Glucoregulatory Physiology in Subjects with Low-Normal, High-Normal, or Impaired Fasting Glucose. J. Clin. Endocrinol. Metab. 2009, 94, 2031–2036. [Google Scholar] [CrossRef]
  63. Kabisch, S.; Meyer, N.M.T.; Honsek, C.; Gerbracht, C.; Dambeck, U.; Kemper, M.; Osterhoff, M.A.; Birkenfeld, A.L.; Arafat, A.M.; Hjorth, M.F.; et al. Fasting Glucose State Determines Metabolic Response to Supplementation with Insoluble Cereal Fibre: A Secondary Analysis of the Optimal Fibre Trial (OptiFiT). Nutrients 2019, 11, 2385. [Google Scholar] [CrossRef] [Green Version]
  64. Mohan, R.; Jose, S.; Mulakkal, J.; Karpinsky-Semper, D.; Swick, A.G.; Krishnakumar, I.M. Water-soluble polyphenol-rich clove extract lowers pre- and post-prandial blood glucose levels in healthy and prediabetic volunteers: An open label pilot study. BMC Complement. Altern. Med. 2019, 19, 99. [Google Scholar] [CrossRef]
  65. Shoji, T.; Yamada, M.; Miura, T.; Nagashima, K.; Ogura, K.; Inagaki, N.; Maeda-Yamamoto, M. Chronic administration of apple polyphenols ameliorates hyperglycaemia in high-normal and borderline subjects: A randomised, placebo-controlled trial. Diabetes Res. Clin. Pr. 2017, 129, 43–51. [Google Scholar] [CrossRef] [PubMed]
  66. Cho, Y.-Y.; Baek, N.-I.; Chung, H.-G.; Jeong, T.-S.; Lee, K.T.; Jeon, S.-M.; Kim, H.-J.; McGregor, R.A.; Choi, M.-S. Randomized controlled trial of Sajabalssuk (Artemisia princeps Pampanini) to treat pre-diabetes. Eur. J. Integr. Med. 2012, 4, e299–e308. [Google Scholar] [CrossRef]
  67. Choi, J.-Y.; Shin, S.-K.; Jeon, S.-M.; Baek, N.-I.; Chung, H.-G.; Jeong, T.-S.; Lee, K.T.; Lee, M.-K.; Choi, M.-S. Dose–Response Study of Sajabalssuk Ethanol Extract from Artemisia princeps Pampanini on Blood Glucose in Subjects with Impaired Fasting Glucose or Mild Type 2 Diabetes. J. Med. Food 2011, 14, 101–107. [Google Scholar] [CrossRef] [PubMed]
  68. Kalman, D.S.; Schwartz, H.I.; Feldman, S.; Krieger, D.R. Efficacy and safety of Elaeis guineensis and Ficus deltoidea leaf extracts in adults with pre-diabetes. Nutr. J. 2013, 12, 36. [Google Scholar] [CrossRef] [Green Version]
  69. Choi, M.-S.; Ryu, R.; Seo, Y.R.; Jeong, T.-S.; Shin, D.-H.; Park, Y.B.; Kim, S.R.; Jung, U.J. The beneficial effect of soybean (Glycine max (L.) Merr.) leaf extracts in adults with prediabetes: A randomized placebo controlled trial. Food Funct. 2014, 5, 1621–1630. [Google Scholar] [CrossRef] [PubMed]
  70. Ryu, R.; Jeong, T.-S.; Kim, Y.J.; Choi, J.-Y.; Cho, S.-J.; Kwon, E.-Y.; Jung, U.J.; Ji, H.-S.; Shin, D.-H.; Choi, M.-S. Beneficial Effects of Pterocarpan-High Soybean Leaf Extract on Metabolic Syndrome in Overweight and Obese Korean Subjects: Randomized Controlled Trial. Nutrients 2016, 8, 734. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  71. Hwang, S.H.; Li, H.M.; Lim, S.S.; Wang, Z.; Hong, J.S.; Huang, B. Evaluation of a Standardized Extract from Morus alba against alpha-Glucosidase Inhibitory Effect and Postprandial Antihyperglycemic in Patients with Impaired Glucose Tolerance: A Randomized Double-Blind Clinical Trial. Evid.-Based Complementary Altern. Med. 2016, 2016, 10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Asai, A.; Nakagawa, K.; Higuchi, O.; Kimura, T.; Kojima, Y.; Kariya, J.; Miyazawa, T.; Oikawa, S. Effect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism. J. Diabetes Investig. 2011, 2, 318–323. [Google Scholar] [CrossRef]
  73. Kim, J.Y.; Ok, H.M.; Kim, J.; Park, S.W.; Kwon, S.W.; Kwon, O. Mulberry Leaf Extract Improves Postprandial Glucose Response in Prediabetic Subjects: A Randomized, Double-Blind Placebo-Controlled Trial. J. Med. Food 2014, 18, 306–313. [Google Scholar] [CrossRef]
  74. Liu, Y.; Zhang, J.; Guo, H.; Zhao, A.; Shao, D.; Dong, Z.; Sun, Y.; Fan, Y.; Yang, F.; Li, P.; et al. Effects of mulberry leaf and white kidney bean extract mix on postprandial glycaemic control in pre-diabetic subjects aged 45–65 years: A randomized controlled trial. J. Funct. Foods 2020, 73, 104117. [Google Scholar] [CrossRef]
  75. Khan, M.M.; Tran, B.Q.; Jang, Y.-J.; Park, S.-H.; Fondrie, W.E.; Chowdhury, K.; Yoon, S.H.; Goodlett, D.R.; Chae, S.-W.; Chae, H.-J.; et al. Assessment of the Therapeutic Potential of Persimmon Leaf Extract on Prediabetic Subjects. Mol. Cells 2017, 40, 466–475. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Hwang, J.-T.; Yang, H.J.; Ha, K.-C.; So, B.-O.; Choi, E.-K.; Chae, S.-W. A randomized, double-blind, placebo-controlled clinical trial to investigate the anti-diabetic effect of Citrus junos Tanaka peel. J. Funct. Foods 2015, 18, 532–537. [Google Scholar] [CrossRef]
  77. Ogawa, S.; Matsumae, T.; Kataoka, T.; Yazaki, Y.; Yamaguchi, H. Effect of acacia polyphenol on glucose homeostasis in subjects with impaired glucose tolerance: A randomized multicenter feeding trial. Exp. Ther. Med. 2013, 5, 1566–1572. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Jung, U.J.; Baek, N.I.; Chung, H.G.; Bang, M.H.; Yoo, J.S.; Jeong, T.S.; Lee, K.T.; Kang, Y.J.; Lee, M.K.; Kim, H.J.; et al. The anti-diabetic effects of ethanol extract from two variants of Artemisia princeps Pampanini in C57BL/KsJ-db/db mice. Food Chem. Toxicol. 2007, 45, 2022–2029. [Google Scholar] [CrossRef]
  79. Kim, M.-J.; Han, J.-M.; Jin, Y.-Y.; Baek, N.-I.; Bang, M.-H.; Chung, H.-G.; Choi, M.-S.; Lee, K.-T.; Sok, D.-E.; Jeong, T.-S. In Vitro antioxidant and anti-inflammatory activities of Jaceosidin from Artemisia princeps Pampanini cv. Sajabal. Arch. Pharmacal Res. 2008, 31, 429–437. [Google Scholar] [CrossRef]
  80. Eddouks, M.; Maghrani, M.; Lemhadri, A.; Ouahidi, M.-L.; Jouad, H. Ethnopharmacological survey of medicinal plants used for the treatment of diabetes mellitus, hypertension and cardiac diseases in the south-east region of Morocco (Tafilalet). J. Ethnopharmacol. 2002, 82, 97–103. [Google Scholar] [CrossRef]
  81. Tahraoui, A.; EL Hilaly, J.; Israili, Z.; Lyoussi, B. Ethnopharmacological survey of plants used in the traditional treatment of hypertension and diabetes in south-eastern Morocco (Errachidia province). J. Ethnopharmacol. 2007, 110, 105–117. [Google Scholar] [CrossRef]
  82. Ryu, S.N.; Han, S.S.; Yang, J.J.; Jeong, H.G.; Kang, S.S. Variation of eupatilin and jaceosidin content of mugwort. Korean J. Crop. Sci. 2005, 50, 204–207. [Google Scholar]
  83. Kang, Y.J.; Jung, U.J.; Lee, M.K.; Kim, H.J.; Jeon, S.M.; Park, Y.B.; Chung, H.G.; Baek, N.I.; Lee, K.T.; Jeong, T.S.; et al. Eupatilin, isolated from Artemisia princeps Pampanini, enhances hepatic glucose metabolism and pancreatic beta-cell function in type 2 diabetic mice. Diabetes Res. Clin. Pract. 2008, 82, 25–32. [Google Scholar] [CrossRef] [PubMed]
  84. Yamamoto, N.; Kanemoto, Y.; Ueda, M.; Kawasaki, K.; Fukuda, I.; Ashida, H. Anti-obesity and anti-diabetic effects of ethanol extract of Artemisia princeps in C57BL/6 mice fed a high-fat diet. Food Funct. 2011, 2, 45–52. [Google Scholar] [CrossRef]
  85. Rosalina Tan, R.T.; Mohamed, S.; Samaneh, G.F.; Noordin, M.M.; Goh, Y.M.; Manap, M.Y. Polyphenol rich oil palm leaves extract reduce hyperglycaemia and lipid oxidation in STZ-rats. Int. Food Res. J. 2011, 18, 179–188. [Google Scholar]
  86. Rajavel, V.; Sattar, M.Z.A.; Abdulla, M.A.; Kassim, N.M.; Abdullah, N.A. Chronic Administration of Oil Palm (Elaeis guineensis) Leaves Extract Attenuates Hyperglycaemic-Induced Oxidative Stress and Improves Renal Histopathology and Function in Experimental Diabetes. Evid.-Based Complement. Altern. Med. 2012, 2012, 1–12. [Google Scholar] [CrossRef] [Green Version]
  87. Jaffri, J.M.; Mohamed, S.; Rohimi, N.; Ahmad, I.N.; Noordin, M.M.; Manap, M.Y.A. Antihypertensive and Cardiovascular Effects of Catechin-Rich Oil Palm (Elaeis guineensis) Leaf Extract in Nitric Oxide–Deficient Rats. J. Med. Food 2011, 14, 775–783. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  88. Tahir, N.I.; Shaari, K.; Abas, F.; Parveez, G.K.A.; Ishak, Z.; Ramli, U.S. Characterization of Apigenin and Luteolin Derivatives from Oil Palm (Elaeis guineensis Jacq.) Leaf Using LC–ESI-MS/MS. J. Agric. Food Chem. 2012, 60, 11201–11210. [Google Scholar] [CrossRef]
  89. Abeywardena, M.; Runnie, I.; Nizar, M.; Head, R.; Momamed, S. Polyphenol-enriched extract of oil palm fronds (Elaeis guineensis) promotes vascular relaxation via endothelium-dependent mechanisms. Asia Pac. J. Clin. Nutr. 2002, 11, S467–S472. [Google Scholar] [CrossRef]
  90. Choi, J.S.; Islam, N.; Ali, Y.; Kim, E.J.; Kim, Y.M.; Jung, H.A. Effects of C-glycosylation on anti-diabetic, anti-Alzheimer’s disease and anti-inflammatory potential of apigenin. Food Chem. Toxicol. 2014, 64, 27–33. [Google Scholar] [CrossRef]
  91. Ruiz, P.A.; Haller, D. Functional diversity of flavonoids in the inhibition of the proinflammatory NF-kappa B, IRF, and Akt signaling pathways in murine intestinal epithelial cells. J. Nutr. 2006, 136, 664–671. [Google Scholar] [CrossRef] [Green Version]
  92. Bunawan, H.; Amin, N.M.; Bunawan, S.N.; Baharum, S.N.; Noor, N.M. Ficus deltoideaJack: A Review on Its Phytochemical and Pharmacological Importance. Evid.-Based Complement. Altern. Med. 2014, 2014, 902734. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Hakiman, M.; Maziah, M. Non enzymatic and enzymatic antioxidant activities in aqueous extract of different Ficus deltoidea accessions. J. Med. Plants Res. 2009, 3, 120–131. [Google Scholar]
  94. Omar, M.H.; Mullen, W.; Crozier, A. Identification of Proanthocyanidin Dimers and Trimers, Flavone C-Glycosides, and Antioxidants in Ficus deltoidea, a Malaysian Herbal Tea. J. Agric. Food Chem. 2011, 59, 1363–1369. [Google Scholar] [CrossRef] [PubMed]
  95. Abdel-Rahman, R.F.; Ezzat, S.M.; Ogaly, H.A.; Abd-Elsalam, R.M.; Hessin, A.F.; Fekry, M.I.; Mansour, D.F.; Mohamed, S.O. Ficus deltoidea extract down-regulates protein tyrosine phosphatase 1B expression in a rat model of type 2 diabetes mellitus: A new insight into its antidiabetic mechanism. J. Nutr. Sci. 2020, 9, 18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Yahaya, N.; Dom, N.S.M.; Adam, Z.; Hamid, M. Insulinotropic Activity of Standardized Methanolic Extracts of Ficus deltoidea from Seven Varieties. Evid.-Based Complement. Altern. Med. 2018, 2018, 3769874. [Google Scholar] [CrossRef] [Green Version]
  97. Adam, Z.; Khamis, S.; Ismail, A.; Hamid, M. Ficus deltoidea: A Potential Alternative Medicine for Diabetes Mellitus. Evid.-Based Complement. Altern. Med. 2012, 2012, 632763. [Google Scholar] [CrossRef] [Green Version]
  98. Aminudin, N.; Chung, Y.S.; Chee, E.S.; Kang, I.N.; Lee, R. Blood glucose lowering effect of Ficus deltoidea aqueous extract. Malays. J. Sci. 2007, 26, 73–78. [Google Scholar]
  99. Adam, Z.; Khamis, S.; Ismail, A.; Hamid, M. Inhibitory Properties of Ficus deltoidea on α-Glucosidase Activity. Res. J. Med. Plant 2010, 4, 61–75. [Google Scholar] [CrossRef]
  100. Choo, C.; Sulong, N.; Man, F.; Wong, T. Vitexin and isovitexin from the Leaves of Ficus deltoidea with in-vivo α-glucosidase inhibition. J. Ethnopharmacol. 2012, 142, 776–781. [Google Scholar] [CrossRef]
  101. Ilyanie, Y.; Wong, T.W.; Choo, C.-Y. Evaluation of Hypoglycemic Activity and Toxicity Profiles of the Leaves of Ficus deltoidea in Rodents. J. Complement. Integr. Med. 2011, 8. [Google Scholar] [CrossRef]
  102. Shafaei, A.; Farsi, E.; Ahamed, M.B.K.; Siddiqui, M.A.; Attitalla, I.H.; Zhari, I.; Asmawi, M.Z. Evaluation of Toxicological and Standardization Parameters and Phytochemical Investigation of Ficus deltoidea Leaves. Am. J. Biochem. Mol. Biol. 2011, 1, 237–243. [Google Scholar] [CrossRef] [Green Version]
  103. Farsi, E.; Ahmad, M.; Hor, S.Y.; Ahamed, M.B.K.; Yam, M.F.; Asmawi, M.Z. Standardized extract of Ficus deltoidea stimulates insulin secretion and blocks hepatic glucose production by regulating the expression of glucose-metabolic genes in streptozitocin-induced diabetic rats. BMC Complement. Altern. Med. 2014, 14, 220. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Adam, Z.; Ismail, A.; Khamis, S.; Mokhtar, M.H.; Hamid, M. Antihyperglycemic Activity of F. deltoidea Ethanolic Extract in Normal Rats. Sains Malays. 2011, 40, 489–495. [Google Scholar]
  105. Nurdiana, S.; Goh, Y.M.; Ahmad, H.; Dom, S.M.; Azmi, N.S.; Zin, N.S.N.M.; Ebrahimi, M. Changes in pancreatic histology, insulin secretion and oxidative status in diabetic rats following treatment with Ficus deltoidea and vitexin. BMC Complement. Altern. Med. 2017, 17, 290. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  106. Farsi, E.; Shafaei, A.; Hor, S.Y.; Ahamed, M.B.; Attitalla, I.H.; Asmawi, Z.; Ismail, Z. Farsi Correlation between enzymes inhibitory effects and antioxidant activities of standardized fractions of methanolic extract obtained from Ficus deltoidea leaves. Afr. J. Biotechnol. 2011, 10, 15184–15194. [Google Scholar] [CrossRef] [Green Version]
  107. Kim, U.H.; Yoon, J.H.; Li, H.; Kang, J.H.; Ji, H.S.; Park, K.H.; Shin, D.H.; Park, H.Y.; Jeong, T.S. Pterocarpan-Enriched Soy Leaf Extract Ameliorates Insulin Sensitivity and Pancreatic beta-Cell Proliferation in Type 2 Diabetic Mice. Molecules 2014, 19, 18493–18510. [Google Scholar] [CrossRef]
  108. Yuk, H.J.; Lee, J.H.; Long, M.; Lee, J.W.; Kim, Y.S.; Ryu, H.W.; Park, C.G.; Jeong, T.-S.; Park, K.H. The most abundant polyphenol of soy leaves, coumestrol, displays potent α-glucosidase inhibitory activity. Food Chem. 2011, 126, 1057–1063. [Google Scholar] [CrossRef]
  109. Zang, Y.; Sato, H.; Igarashi, K. Anti-Diabetic Effects of a Kaempferol Glycoside-Rich Fraction from Unripe Soybean (Edamame, Glycine max L. Merrill. ‘Jindai’) Leaves on KK-AyMice. Biosci. Biotechnol. Biochem. 2011, 75, 1677–1684. [Google Scholar] [CrossRef] [Green Version]
  110. Ho, H.M.; Chen, R.Y.; Leung, L.K.; Chan, F.L.; Huang, Y.; Chen, Z.-Y. Difference in flavonoid and isoflavone profile between soybean and soy leaf. Biomed. Pharmacother. 2002, 56, 289–295. [Google Scholar] [CrossRef]
  111. Yuk, H.J.; Curtis-Long, M.J.; Ryu, H.W.; Jang, K.C.; Seo, W.D.; Kim, J.Y.; Kang, K.Y.; Park, K.H. Pterocarpan Profiles for Soybean Leaves at Different Growth Stages and Investigation of Their Glycosidase Inhibitions. J. Agric. Food Chem. 2011, 59, 12683–12690. [Google Scholar] [CrossRef]
  112. Zhang, Y.; Liu, D. Flavonol kaempferol improves chronic hyperglycemia-impaired pancreatic beta-cell viability and insulin secretory function. Eur. J. Pharmacol. 2011, 670, 325–332. [Google Scholar] [CrossRef] [PubMed]
  113. Kim, J.E.; Jeon, S.M.; Park, K.H.; Lee, W.S.; Jeong, T.S.; McGregor, R.A.; Choi, M.S. Does Glycine max leaves or Garcinia Cambogia promote weight-loss or lower plasma cholesterol in overweight individuals: A randomized control trial. Nutr. J. 2011, 10, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Li, H.; Ji, H.S.; Kang, J.H.; Shin, D.H.; Park, H.Y.; Choi, M.S.; Lee, C.H.; Lee, I.K.; Yun, B.S.; Jeong, T.S. Soy Leaf Extract Containing Kaempferol Glycosides and Pheophorbides Improves Glucose Homeostasis by Enhancing Pancreatic beta-Cell Function and Suppressing Hepatic Lipid Accumulation in db/db Mice. J. Agric. Food Chem. 2015, 63, 7198–7210. [Google Scholar] [CrossRef]
  115. Zang, Y.; Zhang, L.; Igarashi, K.; Yu, C. The anti-obesity and anti-diabetic effects of kaempferol glycosides from unripe soybean leaves in high-fat-diet mice. Food Funct. 2015, 6, 834–841. [Google Scholar] [CrossRef] [PubMed]
  116. Gryn-Rynko, A.; Bazylak, G.; Olszewska-Słonina, D. New potential phytotherapeutics obtained from white mulberry (Morus alba L.) leaves. Biomed. Pharmacother. 2016, 84, 628–636. [Google Scholar] [CrossRef]
  117. Phimarn, W.; Wichaiyo, K.; Silpsavikul, K.; Sungthong, B.; Saramunee, K. A meta-analysis of efficacy of Morus alba Linn. to improve blood glucose and lipid profile. Eur. J. Nutr. 2016, 56, 1509–1521. [Google Scholar] [CrossRef] [PubMed]
  118. Shin, S.-O.; Seo, H.-J.; Park, H.; Song, H.J. Effects of mulberry leaf extract on blood glucose and serum lipid profiles in patients with type 2 diabetes mellitus: A systematic review. Eur. J. Integr. Med. 2016, 8, 602–608. [Google Scholar] [CrossRef]
  119. Kim, J.Y.; Chung, H.I.; Jung, K.-O.; Wee, J.-H.; Kwon, O. Chemical profiles and hypoglycemic activities of mulberry leaf extracts vary with ethanol concentration. Food Sci. Biotechnol. 2013, 22, 1–5. [Google Scholar] [CrossRef]
  120. Hunyadi, A.; Martins, A.; Hsieh, T.-J.; Seres, A.; Zupkó, I. Chlorogenic Acid and Rutin Play a Major Role in the In Vivo Anti-Diabetic Activity of Morus alba Leaf Extract on Type II Diabetic Rats. PLoS ONE 2012, 7, e50619. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  121. Hu, X.-Q.; Jiang, L.; Zhang, J.-G.; Deng, W.; Wang, H.-L.; Wei, Z.-J. Quantitative determination of 1-deoxynojirimycin in mulberry leaves from 132 varieties. Ind. Crop. Prod. 2013, 49, 782–784. [Google Scholar] [CrossRef]
  122. Naowaboot, J.; Pannangpetch, P.; Kukongviriyapan, V.; Prawan, A.; Kukongviriyapan, U.; Itharat, A. Mulberry Leaf Extract Stimulates Glucose Uptake and GLUT4 Translocation in Rat Adipocytes. Am. J. Chin. Med. 2012, 40, 163–175. [Google Scholar] [CrossRef]
  123. Zhang, L.; Su, S.; Zhu, Y.; Guo, J.; Guo, S.; Qian, D.; Ouyang, Z.; Duan, J.A. Mulberry leaf active components alleviate type 2 diabetes and its liver and kidney injury in db/db mice through insulin receptor and TGF-beta/Smads signaling pathway. Biomed. Pharmacother. 2019, 112, 13. [Google Scholar] [CrossRef]
  124. Sánchez-Salcedo, E.M.; Tassotti, M.; Del Rio, D.; Hernández, F.; Martínez, J.J.; Mena, P. (Poly)phenolic fingerprint and chemometric analysis of white (Morus alba L.) and black (Morus nigra L.) mulberry leaves by using a non-targeted UHPLC–MS approach. Food Chem. 2016, 212, 250–255. [Google Scholar] [CrossRef] [PubMed]
  125. Kwon, H.J.; Chung, J.Y.; Kim, J.Y.; Kwon, O. Comparison of 1-Deoxynojirimycin and Aqueous Mulberry Leaf Extract with Emphasis on Postprandial Hypoglycemic Effects: In Vivo and in Vitro Studies. J. Agric. Food Chem. 2011, 59, 3014–3019. [Google Scholar] [CrossRef] [PubMed]
  126. Voss, A.A.; Díez-Sampedro, A.; Hirayama, B.A.; Loo, D.D.F.; Wright, E.M. Imino Sugars Are Potent Agonists of the Human Glucose Sensor SGLT3. Mol. Pharmacol. 2007, 71, 628–634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  127. Liu, C.; Xiang, W.; Yu, Y.; Shi, Z.Q.; Huang, X.Z.; Xu, L. Comparative analysis of 1-deoxynojirimycin contribution degree to alpha-glucosidase inhibitory activity and physiological distribution in Morus alba L. Ind. Crop. Prod. 2015, 70, 309–315. [Google Scholar] [CrossRef]
  128. Jeszka-Skowron, M.; Flaczyk, E.; Jeszka, J.; Krejpcio, Z.; Król, E.; Buchowski, M.S. Mulberry leaf extract intake reduces hyperglycaemia in streptozotocin (STZ)-induced diabetic rats fed high-fat diet. J. Funct. Foods 2014, 8, 9–17. [Google Scholar] [CrossRef]
  129. Chung, H.I.; Kim, J.; Kim, J.Y.; Kwon, O. Acute intake of mulberry leaf aqueous extract affects postprandial glucose response after maltose loading: Randomized double-blind placebo-controlled pilot study. J. Funct. Foods 2013, 5, 1502–1506. [Google Scholar] [CrossRef]
  130. Adisakwattana, S.; Ruengsamran, T.; Kampa, P.; Sompong, W. In vitro inhibitory effects of plant-based foods and their combinations on intestinal α-glucosidase and pancreatic α-amylase. BMC Complement. Altern. Med. 2012, 12, 110. [Google Scholar] [CrossRef] [Green Version]
  131. Kimura, T.; Nakagawa, K.; Kubota, H.; Kojima, Y.; Goto, Y.; Yamagishi, K.; Oita, S.; Oikawa, S. Food-Grade Mulberry Powder Enriched with 1-Deoxynojirimycin Suppresses the Elevation of Postprandial Blood Glucose in Humans. J. Agric. Food Chem. 2007, 55, 5869–5874. [Google Scholar] [CrossRef]
  132. Riche, D.M.; Riche, K.D.; East, H.E.; Barrett, E.K.; May, W.L. Impact of mulberry leaf extract on type 2 diabetes (Mul-DM): A randomized, placebo-controlled pilot study. Complement. Ther. Med. 2017, 32, 105–108. [Google Scholar] [CrossRef] [PubMed]
  133. Lown, M.; Fuller, R.; Lightowler, H.; Fraser, A.; Gallagher, A.; Stuart, B.; Byrne, C.; Lewith, G. Mulberry-extract improves glucose tolerance and decreases insulin concentrations in normoglycaemic adults: Results of a randomised double-blind placebo-controlled study. PLoS ONE 2017, 12, e0172239. [Google Scholar] [CrossRef] [PubMed]
  134. Nakamura, M.; Nakamura, S.; Oku, T. Suppressive response of confections containing the extractive from leaves of Morus Alba on postprandial blood glucose and insulin in healthy human subjects. Nutr. Metab. 2009, 6, 29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  135. Mudra, M.; Ercan-Fang, N.; Zhong, L.; Furne, J.; Levitt, M. Influence of Mulberry Leaf Extract on the Blood Glucose and Breath Hydrogen Response to Ingestion of 75 g Sucrose by Type 2 Diabetic and Control Subjects. Diabetes Care 2007, 30, 1272–1274. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  136. Józefczuk, J.; Malikowska, K.; Glapa, A.; Stawińska-Witoszyńska, B.; Nowak, J.K.; Bajerska, J.; Lisowska, A.; Walkowiak, J. Mulberry leaf extract decreases digestion and absorption of starch in healthy subjects—A randomized, placebo-controlled, crossover study. Adv. Med Sci. 2017, 62, 302–306. [Google Scholar] [CrossRef] [PubMed]
  137. Wang, R.; Li, Y.; Mu, W.; Li, Z.; Sun, J.; Wang, B.; Zhong, Z.; Luo, X.; Xie, C.; Huang, Y. Mulberry leaf extract reduces the glycemic indexes of four common dietary carbohydrates. Medicine 2018, 97, e11996. [Google Scholar] [CrossRef] [PubMed]
  138. Banu, S.; Jabir, N.R.; Manjunath, N.C.; Khan, M.S.; Ashraf, G.M.; Kamal, M.A.; Tabrez, S. Reduction of post-prandial hyperglycemia by mulberry tea in type-2 diabetes patients. Saudi J. Biol. Sci. 2015, 22, 32–36. [Google Scholar] [CrossRef] [Green Version]
  139. Nakamura, S.; Hashiguchi, M.; Yamaguchi, Y. Hypoglycemic Effects of Morus alba Leaf Extract on Postprandial Glucose and Insulin Levels in Patients with Type 2 Diabetes Treated with Sulfonylurea Hypoglycemic Agents. J. Diabetes Metab. 2011, 2, 1–5. [Google Scholar] [CrossRef] [Green Version]
  140. Jung, U.J.; Park, Y.B.; Kim, S.R.; Choi, M.-S. Supplementation of Persimmon Leaf Ameliorates Hyperglycemia, Dyslipidemia and Hepatic Fat Accumulation in Type 2 Diabetic Mice. PLoS ONE 2012, 7, e49030. [Google Scholar] [CrossRef] [Green Version]
  141. Han, J.; Kang, S.; Choue, R.; Kim, H.; Leem, K.; Chung, S.; Kim, C.-J.; Chung, J. Free radical scavenging effect of Diospyros kaki, Laminaria japonica and Undaria pinnatifida. Fitoterapia 2002, 73, 710–712. [Google Scholar] [CrossRef]
  142. Heras, R.M.-L.; Pinazo, A.; Heredia, A.; Andrés, A. Evaluation studies of persimmon plant (Diospyros kaki) for physiological benefits and bioaccessibility of antioxidants by in vitro simulated gastrointestinal digestion. Food Chem. 2017, 214, 478–485. [Google Scholar] [CrossRef] [PubMed]
  143. Sun, L.; Zhang, J.; Lu, X.; Zhang, L.; Zhang, Y. Evaluation to the antioxidant activity of total flavonoids extract from persimmon (Diospyros kaki L.) leaves. Food Chem. Toxicol. 2011, 49, 2689–2696. [Google Scholar] [CrossRef] [PubMed]
  144. Thuong, P.T.; Lee, C.H.; Dao, T.T.; Nguyen, P.H.; Kim, W.G.; Lee, S.J.; Oh, W.K. Triterpenoids from the Leaves of Diospyros kaki (Persimmon) and Their Inhibitory Effects on Protein Tyrosine Phosphatase 1B. J. Nat. Prod. 2008, 71, 1775–1778. [Google Scholar] [CrossRef]
  145. Wang, L.; Xu, M.L.; Rasmussen, S.K.; Wang, M.H. Vomifoliol 9-O-alpha-arabinofuranosyl (1 -> 6)-beta-D-glucopyranoside from the leaves of Diospyros Kaki stimulates the glucose uptake in HepG2 and 3T3-L1 cells. Carbohydr. Res. 2011, 346, 1212–1216. [Google Scholar] [CrossRef] [PubMed]
  146. Kawakami, K.; Aketa, S.; Nakanami, M.; Iizuka, S.; Hirayama, M. Major Water-Soluble Polyphenols, Proanthocyanidins, in Leaves of Persimmon (Diospyros kaki) and Their α-Amylase Inhibitory Activity. Biosci. Biotechnol. Biochem. 2010, 74, 1380–1385. [Google Scholar] [CrossRef]
  147. Bae, U.-J.; Park, S.-H.; Jung, S.-Y.; Park, B.-H.; Chae, S.-W. Hypoglycemic effects of aqueous persimmon leaf extract in a murine model of diabetes. Mol. Med. Rep. 2015, 12, 2547–2554. [Google Scholar] [CrossRef] [Green Version]
  148. Sancheti, S.; Bafna, M.; Lee, S.H.; Seo, S.Y. Persimmon leaf (Diospyros kaki), a potent alpha-glucosidase inhibitor and antioxidant: Alleviation of postprandial hyperglycemia in normal and diabetic rats. J. Med. Plants Res. 2011, 5, 1652–1658. [Google Scholar]
  149. Yoo, K.M.; Lee, K.W.; Park, J.B.; Lee, H.J.; Hwang, I.K. Variation in Major Antioxidants and Total Antioxidant Activity of Yuzu (Citrus junos Sieb ex Tanaka) during Maturation and between Cultivars. J. Agric. Food Chem. 2004, 52, 5907–5913. [Google Scholar] [CrossRef] [PubMed]
  150. Assefa, A.D.; Saini, R.K.; Keum, Y.S. Extraction of antioxidants and flavonoids from yuzu (Citrus junos Sieb ex Tanaka) peels: A response surface methodology study. J. Food Meas. Charact. 2016, 11, 364–379. [Google Scholar] [CrossRef]
  151. Shim, J.-H.; Chae, J.-I.; Cho, S.-S. Identification and Extraction Optimization of Active Constituents in Citrus junos Seib ex TANAKA Peel and Its Biological Evaluation. Molecules 2019, 24, 680. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  152. Kim, S.H.; Hur, H.J.; Yang, H.J.; Kim, H.J.; Kim, M.J.; Park, J.H.; Sung, M.J.; Kim, M.S.; Kwon, D.Y.; Hwang, J.T. Citrus junos Tanaka Peel Extract Exerts Antidiabetic Effects via AMPK and PPAR-gamma both In Vitro and In Vivo in Mice Fed a High-Fat Diet. Evid.-Based Complementary Altern. Med. 2013, 2013, 8. [Google Scholar]
  153. Yang, H.J.; Hwang, J.T.; Kwon, D.Y.; Kim, M.J.; Kang, S.; Moon, N.R.; Park, S. Yuzu Extract Prevents Cognitive Decline and Impaired Glucose Homeostasis in beta-Amyloid-Infused Rats. J. Nutr. 2013, 143, 1093–1099. [Google Scholar] [CrossRef] [PubMed]
  154. Jung, U.J.; Lee, M.K.; Jeong, K.S.; Choi, M.S. The Hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J. Nutr. 2004, 134, 2499–2503. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  155. Chen, X.; Xiong, J.; Huang, S.; Li, X.; Zhang, Y.; Zhang, L.; Wang, F. Analytical Profiling of Proanthocyanidins from Acacia mearnsii Bark and In Vitro Assessment of Antioxidant and Antidiabetic Potential. Molecules 2018, 23, 2891. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  156. Kusano, R.; Ogawa, S.; Matsuo, Y.; Tanaka, T.; Yazaki, Y.; Kouno, I. α-Amylase and Lipase Inhibitory Activity and Structural Characterization of Acacia Bark Proanthocyanidins. J. Nat. Prod. 2011, 74, 119–128. [Google Scholar] [CrossRef]
  157. Ikarashi, N.; Takeda, R.; Ito, K.; Ochiai, W.; Sugiyama, K. The Inhibition of Lipase and Glucosidase Activities by Acacia Polyphenol. Evid.-Based Complement. Altern. Med. 2011, 2011, 272075. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  158. Xiong, J.; Grace, M.H.; Esposito, D.; Komarnytsky, S.; Wang, F.; Lila, M.A. Polyphenols isolated from Acacia mearnsii bark with anti-inflammatory and carbolytic enzyme inhibitory activities. Chin. J. Nat. Med. 2017, 15, 816–824. [Google Scholar] [CrossRef]
  159. Chen, X.; Xiong, J.; He, L.; Zhang, Y.; Li, X.; Zhang, L.; Wang, F. Effects of In Vitro Digestion on the Content and Biological Activity of Polyphenols from Acacia mearnsii Bark. Molecules 2018, 23, 1804. [Google Scholar] [CrossRef] [Green Version]
  160. Ogawa, S.; Yazaki, Y. Tannins from Acacia mearnsii De Wild. Bark: Tannin Determination and Biological Activities. Molecules 2018, 23, 837. [Google Scholar] [CrossRef] [Green Version]
  161. Neilson, A.P.; O’Keefe, S.F.; Bolling, B.W. High-Molecular-Weight Proanthocyanidins in Foods: Overcoming Analytical Challenges in Pursuit of Novel Dietary Bioactive Components. In Annual Review of Food Science and Technology; Doyle, M.P., Klaenhammer, T.R., Eds.; Annual Reviews: Palo Alto, CA, USA, 2016; Volume 7, pp. 43–64. [Google Scholar]
  162. Xiao, J.; Kai, G.; Yamamoto, K.; Chen, X. Advance in Dietary Polyphenols as α-Glucosidases Inhibitors: A Review on Structure-Activity Relationship Aspect. Crit. Rev. Food Sci. Nutr. 2013, 53, 818–836. [Google Scholar] [CrossRef]
  163. Sun, L.; Miao, M. Dietary polyphenols modulate starch digestion and glycaemic level: A review. Crit. Rev. Food Sci. Nutr. 2020, 60, 541–555. [Google Scholar] [CrossRef] [PubMed]
  164. Balion, C.M.; Raina, P.S.; Gerstein, H.C.; Santaguida, P.L.; Morrison, K.M.; Booker, L.; Hunt, D.L. Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: A systematic review. Clin. Chem. Lab. Med. 2007, 45, 1180–1185. [Google Scholar] [CrossRef] [PubMed]
  165. Buchanan, T.A.; Xiang, A.H.; Peters, R.K.; Kjos, S.L.; Marroquin, A.; Goico, J.; Ochoa, C.; Tan, S.; Berkowitz, K.; Hodis, H.N.; et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51, 2796–2803. [Google Scholar] [CrossRef] [Green Version]
  166. Kahn, S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetol. 2003, 46, 3–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  167. Buchanan, T.A. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin. Ther. 2003, 25, B32–B46. [Google Scholar] [CrossRef]
  168. Salunkhe, V.A.; Veluthakal, R.; Kahn, S.E.; Thurmond, D.C. Novel approaches to restore beta cell function in prediabetes and type 2 diabetes. Diabetol. 2018, 61, 1895–1901. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  169. Samuel, V.T.; Shulman, G.I. Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell 2012, 148, 852–871. [Google Scholar] [CrossRef] [Green Version]
Table
Table 2. Changes in glycemic clinical outcomes of human clinical trials in participants with prediabetes classified by their subgroups. The significant outcomes are presented in sequence first as comparison with control, then comparison within intervention group.
Table 2. Changes in glycemic clinical outcomes of human clinical trials in participants with prediabetes classified by their subgroups. The significant outcomes are presented in sequence first as comparison with control, then comparison within intervention group.
Plant ExtractDoseTotal Phenolic ContentBioactive Compound ConcentrationFasting StatePostprandial StateHbA1cReference
FBGFIFCPHOMA-IRPG/PG AUCPI/PI
AUC		PCP/PCP AUC
Human clinical trials on impaired fasting glucose (IFG)
Artemisia princeps Pampanini (Sajabalssuk) 3000 mg/dayTotal phenolic 232.4 mg GAE/g
Total flavonoid 105.2 mg QE/g		741.2 mg eupatilin /100 g, 610.3 mg jaceosidin /100 g↓, ↓-, -na↓, -nanana↓, ↓[66]
Artemisia princeps Pampanini (Sajabalssuk)2000 mg/dayTotal phenolic 232.4 mg GAE/g
Total flavonoid 105.2 mg QE/g		741.2 mg eupatilin /100 g, 610.3 mg jaceosidin/100 g na, ↓na, -na, -na, -nananana, ↓[67]
4000 mg/dayna, ↓na, -na, -na, -nananana, ↓
Elaeis guineensis leaf 500 mg/dayNot reportedNot reportedna, ↓na, ↓nana, -na, -na, -nana[68]
1000 mg/dayna, -na, -nana, -na, ↓na, ↓nana
Ficus deltoidea leaf1000 mg/dayNot reportedNot reportedna, -na, -nana, -na, -na, -nana
Soy (Glycine max (L.) Merrill) leaf 2000 mg/dayTotal phenolic 54.1 ± 0.5 mg GAE/g
Total flavonoid
90.2 ± 1.3 mg QE/g		2.09 ± 0.04 mg 6”-O-malonygenistin/g, 1.48 ± 0.03 mg coumestrol/g↓, --. -na↓, -nanana↓, -[69]
Pterocarpan-high Soy (Glycine max (L.) Merrill) leaf 2000 mg/dayTotal phenolic 136.7 ± 0.0 mg GAE/g
Total flavonoid
77.3 ± 0.2 mg QE/g		10.85 ± 0.26 μg coumestrol/mg, 5.90 ± 0.11 μg phaseol/mg-, ↓-, ↓na↓, ↓nanana↓, ↓[70]
White mulberry (Morus alba Linn.) leaf and white kidney bean extract1500 mgTotal phenolic 46.7 mg GAE/g
Total flavonoid
2.7 mg QE/g		25 mg DNJ/1.5 g (10% DNJ) nananana ↓ ↓ ↓ na[74]
4500 mg/dayna, nana, nana, na-, na-, na-, na-, na-, na
White mulberry (Morus alba Linn.) leaf and onion extract Cooked rice coated with extract (8.8 mg DNJ)Not reported11.77 ± 1.67 mg DNJ/ 100 g cooked rice nananana ↓ nanana[71]
White mulberry (Morus alba Linn.) leaf Extract with 6 mg DNJNot reported6 mg DNJ-, --, -nanananana-, ↓[72]
White mulberry (Morus alba Linn.) leaf 5000 mg/day
(18 mg DNJ)		Not reported3.6 mg DNJ/g-, na-, na-, nana↓, na↓, na↓, na-, na[73]
Human clinical trials on impaired glucose tolerance (IGT)
Persimmon (Diospyros kaki) leaf 2000 mg/dayNot reported7.5 mg quercetin 3-O-2”galloylglucoside and kaempferol 3-O-2” galloylglucoside/gnananana↓, nananana[75]
Human clinical trials on combined impaired fasting glucose and impaired glucose tolerance (IFG/IGT)
Citrus junos Tanaka peel 4250 mg/dayNot reported2.7 mg rutin/100 g, 1.7 mg quercetin/100 g, 0.7 mg tangeretin/100 g, 11.6 mg naringin/100 g, 36.3 mg hesperidin/100 g↓, -↓, --, ↓↓, --, -nanana[76]
Acacia. Mearnsii bark 250 mg/dayNot reported250 mg acacia polyphenol-, --, -na-, -↓, ↓↓, ↓na-, -[77]
White mulberry (Morus alba Linn.) leaf Extract with 3 mg DNJNot reported3 mg DNJ--nana- ↓ nana[72]
Extract with 6 mg DNJ6 mg DNJ--nana ↓ ↓ nana
Extract with 9 mg DNJ9 mg DNJ--nana ↓ ↓ nana
DNJ: 1-deoxynojirimycin; FBG: fasting blood glucose; FCP: fasting C-peptide; FI: fasting insulin; GAE: gallic acid equivalent; HbA1c: glycated hemoglobin A1c; HOMA-IR: homeostasis model assessment-insulin resistance; IFG: impaired fasting glucose; IFG/IGT: combined impaired fasting glucose and impaired glucose tolerance; IGT: impaired glucose tolerance; PCP: postprandial C-peptide; PCP AUC: area under the curve of postprandial C-peptide; PG: postprandial glucose; PG AUC: area under the curve of postprandial glucose; PI: postprandial insulin; PI AUC: area under the curve of postprandial insulin; RCT: randomized controlled trial; QE: quercetin equivalent; ↓: a significant decrease in the measured value (p < 0.05); -: no significant changes to measured value (p > 0.05); na: not applicable.
Table
Table 3. Hypoglycemic effects of plant extracts on fasting and postprandial glycemic measurements.
Table 3. Hypoglycemic effects of plant extracts on fasting and postprandial glycemic measurements.
Plant Extracts with Potential Hypoglycemic Effects on Fasting Glycemic Measurements
Artemisia princeps Pampanini (Sajabalssuk)
Elaeis guineensis leaf (500 mg/day)
Soy (Glycine max (L.) Merrill) leaf
Citrus junos Tanaka peel
Plant extracts with potential hypoglycemic effects on postprandial glycemic measurements
White mulberry (Morus alba Linn.) leaf
Elaeis guineensis leaf (Higher dose, 1000 mg/day)
Persimmon (Diospyros kaki) leaf
Acacia. Mearnsii bark
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lim, W.X.J.; Gammon, C.S.; von Hurst, P.; Chepulis, L.; Page, R.A. A Narrative Review of Human Clinical Trials on the Impact of Phenolic-Rich Plant Extracts on Prediabetes and Its Subgroups. Nutrients 2021, 13, 3733. https://doi.org/10.3390/nu13113733

AMA Style

Lim WXJ, Gammon CS, von Hurst P, Chepulis L, Page RA. A Narrative Review of Human Clinical Trials on the Impact of Phenolic-Rich Plant Extracts on Prediabetes and Its Subgroups. Nutrients. 2021; 13(11):3733. https://doi.org/10.3390/nu13113733

Chicago/Turabian Style

Lim, Wen Xin Janice, Cheryl S. Gammon, Pamela von Hurst, Lynne Chepulis, and Rachel A. Page. 2021. "A Narrative Review of Human Clinical Trials on the Impact of Phenolic-Rich Plant Extracts on Prediabetes and Its Subgroups" Nutrients 13, no. 11: 3733. https://doi.org/10.3390/nu13113733

APA Style

Lim, W. X. J., Gammon, C. S., von Hurst, P., Chepulis, L., & Page, R. A. (2021). A Narrative Review of Human Clinical Trials on the Impact of Phenolic-Rich Plant Extracts on Prediabetes and Its Subgroups. Nutrients, 13(11), 3733. https://doi.org/10.3390/nu13113733

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop